Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported an automatic share sale related to tax withholding. On March 2, 2026, he sold 7,909 shares of common stock in an open-market transaction at a weighted average price of $14.5216 per share to cover taxes from restricted stock unit vesting.
After this sale, he directly held 165,638 shares. The filing also notes indirect holdings through several trusts, including 100,000 shares, 15,459 shares and 11,072 shares, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of 6,844 shares of common stock on March 2, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $14.5205 per share, and she held 134,430 shares afterward.
Amylyx Pharmaceuticals, Inc. filed an automatic shelf registration on March 3, 2026 to register an offering program for common stock, preferred stock, debt securities, warrants and units to be sold from time to time.
The prospectus states Amylyx is a well-known seasoned issuer using Form S-3ASR and may sell securities on a continuous or delayed basis; specific terms will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol AMLX, with a closing sale price of $15.30 on March 2, 2026.
Amylyx Pharmaceuticals describes its 2025 business, drug pipeline and regulatory context in its annual report. The company had an aggregate market value of common equity held by non‑affiliates of $518.2 million as of June 30, 2025, with 110,536,944 shares outstanding as of February 23, 2026.
The lead asset, avexitide, targets post‑bariatric hypoglycemia affecting an estimated 160,000 people in the U.S. and is in the 75‑patient Phase 3 LUCIDITY trial, with topline data expected in Q3 2026. The report also highlights positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome, initiation and early safety data from the Phase 1 LUMINA trial of AMX0114 in ALS, selection of long‑acting GLP‑1 antagonist AMX0318 for PBH and other rare diseases, and a patent estate including 23 issued U.S. patents and 257 granted foreign patents as of December 31, 2025.
Amylyx Pharmaceuticals reported a smaller net loss for 2025 while pivoting firmly to late-stage development of avexitide for post-bariatric hypoglycemia (PBH). Net loss for 2025 was $144.7 million, or $1.53 per share, about half the $301.7 million, or $4.43 per share, loss in 2024. Product revenue fell from $87.4 million in 2024 to zero in 2025 as the company redirected resources.
Research and development expenses were $90.4 million in 2025, down from $104.1 million, while selling, general, and administrative expenses dropped sharply to $62.9 million from $114.3 million, reflecting reduced consulting and professional services. Cash, cash equivalents, and marketable securities were $317.0 million at December 31, 2025, up from $176.5 million a year earlier, supporting a stated cash runway into 2028.
Operationally, recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete, with last participants expected to be randomized and dosed in Q1 2026 and topline data anticipated in Q3 2026, targeting potential U.S. commercialization in 2027 if approved. The company is also advancing AMX0114 for amyotrophic lateral sclerosis in the Phase 1 LUMINA trial, with Cohort 2 enrollment expected to complete in March 2026, and progressing AMX0318 toward a planned investigational new drug filing in 2027.
Issuer files a Form 144 reporting the sale of common stock tied to vested restricted stock units and recent brokered transactions. The filing lists 22,522 shares associated with a 03/02/2026 vesting event and shows prior sales of 3,326 (01/06/2026) and 3,557 (02/02/2026) by James M. Frates.
The report names Morgan Stanley Smith Barney LLC as the broker and references NASDAQ as the market; timing and cash‑flow details are those shown on the reported trade dates.
AMLX Form 144 notice reports proposed transfer related to the vesting of restricted stock units into Common stock. The filing lists 17,105 shares associated with 03/02/2026 and records a sale of 6,580 Common shares by Camille L Bedrosian on 12/01/2025.
Justin B. Klee filed a Form 144 proposing the sale of 57,529 common shares tied to the vesting of restricted stock units through Morgan Stanley Smith Barney LLC on 03/02/2026. The filing lists prior open‑market sales by Mr. Klee in January–February 2026, including sales of 136,193 shares on 01/15/2026 and 15,500 shares on 02/02/2026.
AMLX lists insider resale activity by Joshua B. Cohen: a planned disposition of 57,529 common shares tied to vesting restricted stock units on 03/02/2026 and multiple sales in the prior three months. The excerpt shows sales of 7,715 (01/06/2026), 136,193 (01/15/2026), 1,974 (01/16/2026), and 15,500 (02/02/2026).
AMLX reports a Form 144 disclosure covering recent transactions in its common stock. The issuer recorded the vesting of 20,545 restricted stock units on 03/02/2026. The filing also lists two sales by Gina Mazzariello of 3,448 shares on 02/02/2026 and 3,419 shares on 02/23/2026.